Benign Prostatic Hyperplasia - Drug Pipeline Landscape, 2023

Benign Prostatic Hyperplasia - Drug Pipeline Landscape, 2023

Benign Prostatic Hyperplasia (BPH) also called as prostate gland enlargement, is a noncancerous increase in size of the prostate gland. An enlarged prostate gland can cause uncomfortable urinary symptoms, such as blocking the flow of urine out of the bladder.

The common causes of BPH include changes in male sex hormones, any family history of prostate problems or any abnormalities with testicles risk of BPH.

Symptoms include incomplete bladder emptying, leakage of urine, obstructing the flow of urine, frequent or urgent need to urinate, increased frequency of urination at night (nocturia), difficulty starting urination, dribbling at the end of urination.

Diagnosis of BPH involves a physical exam and medical history. The physical exam includes a rectal examination to estimate the size and shape of prostate. Diagnostic tests include Urodynamic test, prostate-specific antigen (PSA) test, post-void residual and cystoscopy.

The most common treatments for Benign Prostatic Hyperplasia are medications, minimally invasive therapies and surgery.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Benign Prostatic Hyperplasia treatment such as MCS-2, Fexapotide Triflutate, GV1001 and others. Key players involved in the development of therapies to treat benign prostatic hyperplasia are GemVax & Kael, Health Ever Bio-Tech Co., Ltd, Nymox Corporation, Dongkook Pharmaceutical Co., Ltd, Urovant Sciences GmbH and others. Two drugs are under late-stage Pre-registration, three drugs are under Phase III clinical trials and three drugs are in Phase II clinical trials and some other drugs are under Preclinical and Discovery stages of development.

In December 2022, NYMOX announced that a new formal submission has been made in Europe for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH) under the trademark name “NYMOZARFEX”. The Marketing Authorization Application (MAA) was submitted to the Danish authorities.

Report Highlights

Global Insight Service's, Benign Prostatic Hyperplasia - Drug Pipeline Landscape, 2023 report provides an overview of the Benign Prostatic Hyperplasia pipeline drugs. This report covers detailed insights on Benign Prostatic Hyperplasia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Benign Prostatic Hyperplasia pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.